Ratings Cellectis S.A.

Equities

ALCLS

FR0010425595

Market Closed - Euronext Paris Other stock markets 11:37:12 2024-05-07 am EDT			After market 04:00:00 pm
2.745 ^EUR	-5.51%		2.828	+3.02%

05:29pm	Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesday	MT
May. 06	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
Based on current prices, the company has particularly high valuation levels.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
CELLECTIS S.A.	-0.69%	225M	C
MODERNA, INC.	+21.74%	46.81B	B-
IQVIA HOLDINGS INC.	-0.97%	41.37B	B
LONZA GROUP AG	+47.07%	41.29B	A
CELLTRION, INC.	-3.52%	28.87B	C
ICON PUBLIC LIMITED COMPANY	+11.12%	26.06B	B-
ALNYLAM PHARMACEUTICALS, INC.	-19.37%	19.13B	B
MEDPACE HOLDINGS, INC.	+31.18%	12.39B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.04%	12.08B	C+
BIO-TECHNE CORPORATION	+0.39%	11.96B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes